Skip to main content
Erschienen in: Journal of Nuclear Cardiology 4/2021

29.08.2019 | Original Article

Prognostic usefulness of planar 123I-MIBG scintigraphic images of myocardial sympathetic innervation in congestive heart failure: Follow-Up data from ADMIRE-HF

verfasst von: Denis Agostini, MD, PhD, Karthikeyan Ananthasubramaniam, MD, Harish Chandna, MD, Lars Friberg, MD, Andrew Hudnut, MD, Michael Koren, MD, Michael I. Miyamoto, MD, Roxy Senior, MD, Mahesh Shah, MD, Mark I. Travin, MD, Jürgen vom Dahl, MD, Kun Chen, PhD, Wayne C. Levy, MD, on behalf of the ADMIRE-HF investigators

Erschienen in: Journal of Nuclear Cardiology | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

To evaluate whether planar 123I-MIBG myocardial scintigraphy predicts risk of death in heart failure (HF) patients up to 5 years after imaging.

Methods and Results

Subjects from ADMIRE-HF were followed for approximately 5 years after imaging (964 subjects, median follow-up 62.7 months). Subjects were stratified according to the heart/mediastinum (H/M) ratio (< 1.60 vs ≥ 1.60) on planar 123I-MIBG scintigraphic images obtained at baseline in ADMIRE-HF. Cox proportional hazards models and Kaplan-Meier analyses were used to evaluate time to death, cardiac death, or arrhythmic events for subjects stratified by H/M ratio, baseline left ventricular ejection fraction (LVEF: < 25% and 25 to ≤ 35%), and by H/M strata within LVEF strata. All-cause mortality was 38.4% vs 20.9% and cardiac mortality was 16.8% vs 4.5%, in subjects with H/M < 1.60 vs ≥ 1.60, respectively (P < 0.05 for both comparisons). Subjects with preserved sympathetic innervation of the myocardium (H/M ≥ 1.60) were at significantly lower risk of all-cause and cardiac death, arrhythmic events, sudden cardiac death, or potentially life-threatening arrhythmias. Within LVEF strata, a trend toward a higher mortality for subjects with H/M < 1.60 was observed reaching significance for LVEF 25 to ≤ 35% only.

Conclusions

During a median follow-up of 62.7 months, patients with H/M ≥ 1.60 were at significantly lower risk of death and arrhythmic events independently of LVEF values.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, ADMIRE-HF Investigators, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective AdreView myocardial imaging for risk evaluation in heart failure (ADMIRE-HF) study. J Am Coll Cardiol 2010;55:2212-21. https://doi.org/10.1016/j.jacc.2010.01.014.CrossRefPubMed Jacobson AF, Senior R, Cerqueira MD, Wong ND, Thomas GS, Lopez VA, ADMIRE-HF Investigators, et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective AdreView myocardial imaging for risk evaluation in heart failure (ADMIRE-HF) study. J Am Coll Cardiol 2010;55:2212-21. https://​doi.​org/​10.​1016/​j.​jacc.​2010.​01.​014.CrossRefPubMed
5.
Zurück zum Zitat Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Randé JL, Duval AM, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999;40:917-23.PubMed Merlet P, Benvenuti C, Moyse D, Pouillart F, Dubois-Randé JL, Duval AM, et al. Prognostic value of MIBG imaging in idiopathic dilated cardiomyopathy. J Nucl Med 1999;40:917-23.PubMed
7.
Zurück zum Zitat Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C, Dreyfus G, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: Relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999;33:759-66.CrossRef Cohen-Solal A, Esanu Y, Logeart D, Pessione F, Dubois C, Dreyfus G, et al. Cardiac metaiodobenzylguanidine uptake in patients with moderate chronic heart failure: Relationship with peak oxygen uptake and prognosis. J Am Coll Cardiol 1999;33:759-66.CrossRef
8.
Zurück zum Zitat Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med 2001;42:1757-67.PubMed Wakabayashi T, Nakata T, Hashimoto A, Yuda S, Tsuchihashi K, Travin MI, et al. Assessment of underlying etiology and cardiac sympathetic innervation to identify patients at high risk of cardiac death. J Nucl Med 2001;42:1757-67.PubMed
9.
Zurück zum Zitat Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol 1998;5:579-90.CrossRef Nakata T, Miyamoto K, Doi A, Sasao H, Wakabayashi T, Kobayashi H, et al. Cardiac death prediction and impaired cardiac sympathetic innervation assessed by MIBG in patients with failing and nonfailing hearts. J Nucl Cardiol 1998;5:579-90.CrossRef
12.
Zurück zum Zitat Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;2013:e147-239. https://doi.org/10.1016/j.jacc.2013.05.019.CrossRef Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines, et al. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013;2013:e147-239. https://​doi.​org/​10.​1016/​j.​jacc.​2013.​05.​019.CrossRef
13.
Zurück zum Zitat Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, ESC Scientific Document Group, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;2016:2129-200. https://doi.org/10.1093/eurheartj/ehw128.CrossRef Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, ESC Scientific Document Group, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016;2016:2129-200. https://​doi.​org/​10.​1093/​eurheartj/​ehw128.CrossRef
15.
Zurück zum Zitat Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res 2004;95:754-63.CrossRef Tomaselli GF, Zipes DP. What causes sudden death in heart failure? Circ Res 2004;95:754-63.CrossRef
16.
Zurück zum Zitat Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473-82.CrossRef Huikuri HV, Castellanos A, Myerburg RJ. Sudden death due to cardiac arrhythmias. N Engl J Med 2001;345:1473-82.CrossRef
Metadaten
Titel
Prognostic usefulness of planar 123I-MIBG scintigraphic images of myocardial sympathetic innervation in congestive heart failure: Follow-Up data from ADMIRE-HF
verfasst von
Denis Agostini, MD, PhD
Karthikeyan Ananthasubramaniam, MD
Harish Chandna, MD
Lars Friberg, MD
Andrew Hudnut, MD
Michael Koren, MD
Michael I. Miyamoto, MD
Roxy Senior, MD
Mahesh Shah, MD
Mark I. Travin, MD
Jürgen vom Dahl, MD
Kun Chen, PhD
Wayne C. Levy, MD
on behalf of the ADMIRE-HF investigators
Publikationsdatum
29.08.2019
Verlag
Springer International Publishing
Erschienen in
Journal of Nuclear Cardiology / Ausgabe 4/2021
Print ISSN: 1071-3581
Elektronische ISSN: 1532-6551
DOI
https://doi.org/10.1007/s12350-019-01859-w

Weitere Artikel der Ausgabe 4/2021

Journal of Nuclear Cardiology 4/2021 Zur Ausgabe

Vorsicht, erhöhte Blutungsgefahr nach PCI!

10.05.2024 Koronare Herzerkrankung Nachrichten

Nach PCI besteht ein erhöhtes Blutungsrisiko, wenn die Behandelten eine verminderte linksventrikuläre Ejektionsfraktion aufweisen. Das Risiko ist umso höher, je stärker die Pumpfunktion eingeschränkt ist.

Triglyzeridsenker schützt nicht nur Hochrisikopatienten

10.05.2024 Hypercholesterinämie Nachrichten

Patienten mit Arteriosklerose-bedingten kardiovaskulären Erkrankungen, die trotz Statineinnahme zu hohe Triglyzeridspiegel haben, profitieren von einer Behandlung mit Icosapent-Ethyl, und zwar unabhängig vom individuellen Risikoprofil.

Gibt es eine Wende bei den bioresorbierbaren Gefäßstützen?

In den USA ist erstmals eine bioresorbierbare Gefäßstütze – auch Scaffold genannt – zur Rekanalisation infrapoplitealer Arterien bei schwerer PAVK zugelassen worden. Das markiert einen Wendepunkt in der Geschichte dieser speziellen Gefäßstützen.

Darf man die Behandlung eines Neonazis ablehnen?

08.05.2024 Gesellschaft Nachrichten

In einer Leseranfrage in der Zeitschrift Journal of the American Academy of Dermatology möchte ein anonymer Dermatologe bzw. eine anonyme Dermatologin wissen, ob er oder sie einen Patienten behandeln muss, der eine rassistische Tätowierung trägt.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.